We've found
13,253
archived clinical trials in
Arthritis
We've found
13,253
archived clinical trials in
Arthritis
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Updated: 12/31/1969
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Updated: 12/31/1969
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials